Nurix Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.72) Per Share, HC Wainwright Forecasts (NASDAQ:NRIX)

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Stock analysts at HC Wainwright boosted their Q2 2024 earnings per share (EPS) estimates for shares of Nurix Therapeutics in a research report issued on Tuesday, June 18th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.72) per share for the quarter, up from their previous forecast of ($0.85). HC Wainwright currently has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($3.00) per share. HC Wainwright also issued estimates for Nurix Therapeutics’ Q3 2024 earnings at ($0.68) EPS, Q4 2024 earnings at ($0.71) EPS, FY2024 earnings at ($2.87) EPS, Q1 2025 earnings at ($0.73) EPS, Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.78) EPS and Q4 2025 earnings at ($0.80) EPS.

NRIX has been the topic of several other research reports. Stephens initiated coverage on shares of Nurix Therapeutics in a research report on Tuesday, May 14th. They issued an “overweight” rating and a $20.00 target price on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, May 15th. Robert W. Baird raised their target price on Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a research report on Thursday, April 11th. Piper Sandler reiterated an “overweight” rating and set a $35.00 price target on shares of Nurix Therapeutics in a research report on Wednesday, June 5th. Finally, Needham & Company LLC restated a “buy” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a report on Monday. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $24.80.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX opened at $20.97 on Friday. The firm has a fifty day moving average of $14.99 and a 200 day moving average of $12.24. Nurix Therapeutics has a one year low of $4.22 and a one year high of $21.16.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Wednesday, April 10th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.04. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. The business had revenue of $16.59 million during the quarter, compared to the consensus estimate of $14.58 million.

Institutional Trading of Nurix Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of NRIX. China Universal Asset Management Co. Ltd. boosted its stake in Nurix Therapeutics by 351.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock worth $58,000 after buying an additional 4,367 shares during the period. Quest Partners LLC acquired a new position in shares of Nurix Therapeutics in the 4th quarter worth approximately $59,000. EntryPoint Capital LLC purchased a new position in shares of Nurix Therapeutics during the 1st quarter worth approximately $123,000. Jump Financial LLC purchased a new position in shares of Nurix Therapeutics during the 4th quarter worth approximately $158,000. Finally, Exchange Traded Concepts LLC increased its holdings in Nurix Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 15,823 shares of the company’s stock valued at $163,000 after purchasing an additional 4,012 shares during the last quarter.

Insider Transactions at Nurix Therapeutics

In related news, insider Christine Ring sold 1,900 shares of the company’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $17.01, for a total value of $32,319.00. Following the completion of the sale, the insider now owns 19,838 shares of the company’s stock, valued at $337,444.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Christine Ring sold 1,900 shares of Nurix Therapeutics stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $17.01, for a total transaction of $32,319.00. Following the sale, the insider now owns 19,838 shares of the company’s stock, valued at approximately $337,444.38. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Houte Hans Van sold 3,499 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $12.83, for a total value of $44,892.17. Following the completion of the transaction, the chief financial officer now owns 68,333 shares of the company’s stock, valued at $876,712.39. The disclosure for this sale can be found here. Insiders have sold a total of 10,789 shares of company stock worth $152,023 in the last quarter. Company insiders own 7.20% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.